What Is Genotropin?

1. What does the label cover?

The current US label, revised in July 2026, approves Genotropin for six uses.

Height SDS (standard deviation score) is height expressed as standard deviations from the average for age and sex; −2.25 is shorter than roughly 99% of peers.

For adults, the label says the diagnosis should normally be confirmed with a GH stimulation test. The exceptions are people with several other pituitary hormone deficiencies from organic disease and people with congenital or genetic GH deficiency. Children treated for GH deficiency whose growth plates have closed should be re-tested before continuing at the lower adult dose.

The label does not cover aging, athletic performance, body composition in people with normal GH, or weight loss.

2. How is Genotropin dosed?

The label sets a weekly dose by condition and splits it into 6 or 7 injections under the skin. It must not be injected into a vein. Doses are individualized by growth response in children and by response and IGF-1 in adults (Genotropin label).

For SGA, the label notes that published guidance favors starting higher, around 0.48 mg/kg/week, in very short or older children and stepping down toward 0.24 mg/kg/week if catch-up is strong. Younger children with milder shortness may start at 0.24. Treatment for short stature stops when the growth plates fuse.

Adults have two options on the label:

Older adults and people with obesity are more prone to side effects, so the label suggests lower starting doses and smaller steps. Women with normal estrogen levels, and especially those on oral estrogen, may need higher doses than men. The dose is lowered if IGF-1 rises above the normal range for age and sex. The general idea of stepwise changes is covered in the dose titration guide.

3. Which pens and devices does Genotropin come in?

Genotropin is a powder. Every form is a two-chamber cartridge, with the hormone in the front chamber and the liquid in the rear; the device mixes them before the first dose.

The color coding is meant to stop the wrong cartridge going into the wrong pen. The label describes each reusable pen as a device for mixing and injecting over a 2-year use period. Before mixing, MiniQuick can be kept at room temperature, at or below 77°F (25°C), for up to 3 months. The 5 mg and 12 mg cartridges contain m-cresol as a preservative, which matters for anyone allergic to it.

GoQuick is a prefilled pen that Pfizer sells in the UK and other markets. It is not listed on the current US label. The UK Pituitary Foundation describes it as a disposable pen that can be used for about a month. In 2015, the UK regulator MHRA issued a caution about the GoQuick 5.3 mg and 12 mg pens: turning the dose knob with excessive force could set one extra click, adding about 0.05 mg or 0.15 mg. Batches were not recalled, to avoid a shortage, and patients were reminded to check the dose window.

Supply in 2026

On February 27, 2026, the Pituitary Foundation reported that the reusable Genotropin pen was out of stock in the UK in both the 5 mg and 12 mg strengths, and expected to remain so until at least early 2027. MiniQuick and GoQuick stayed available, and current reusable-pen users were to be switched to another device when their pen’s battery ran out. When I checked the openFDA drug shortage database in November 2026, it had no Genotropin entry.

4. What did the trials and registries show?

The label summarizes the trials behind each indication (Genotropin label):

In the PWS trials, body weight changed similarly in treated and untreated children (3.7 vs 3.5 kg), while lean mass rose 4.7 kg versus 0.7 kg. A 2025 meta-analysis of 41 PWS studies found GH raised height SDS and lowered BMI SDS compared with no GH, but also raised LDL cholesterol and blood glucose. It estimated mortality during GH treatment at 1.5%, with causes including respiratory problems, cardiac arrest and infections, which is why the label’s PWS warnings are strict.

The registries

Pfizer has followed Genotropin users in two large observational studies. KIGS, the Kabi International Growth Study, began in 1987 and is the largest pharmaco-epidemiological study of GH in children, with 129 peer-reviewed papers from its data (Geffner et al., 2024). It is still used as a reference; a 2026 analysis matched 155 KIGS children on daily Genotropin with 155 on weekly somatrogon and found similar height velocity in years 1 to 3.

KIMS, the adult counterpart, followed 15,809 GH-treated adults for a mean of 5.3 years (Johannsson et al., 2022). Adverse events were reported in 51.2% (treatment-related in 18.8%), and their rate did not track GH dose after adjustment. New cancer incidence was similar to the general population (standardized incidence ratio 0.92, 95% CI 0.83–1.01) and lower in people with idiopathic or congenital GH deficiency. Lipids and fasting glucose showed neutral changes. A 2026 review of SGA registry data across KIGS and other brand registries reported a low rate of serious adverse events and no excess metabolic or cancer risk compared with background rates. All three registries are manufacturer-run observational studies without control groups.

5. What are the side effects and warnings?

Genotropin has no boxed warning. In adult trials, fluid-retention symptoms dominated, usually early in treatment and responsive to dose reduction (Genotropin label):

Most of these fell to placebo-like rates after 6 months. In extension studies of 3,031 adults, 12 (0.4%) developed diabetes, all with predisposing factors such as obesity or raised HbA1c, and 61 (2%) had carpal tunnel symptoms. In children, the label lists injection site reactions, lipoatrophy (fat loss at the injection site), headache, blood in the urine, hypothyroidism and mild high blood sugar as infrequent. Antibodies to GH developed in 8 of 413 children (1.9%), none at levels that affected growth.

Contraindications and main warnings:

• acute critical illness after heart or abdominal surgery, major trauma or respiratory failure; in two ICU trials, high-dose GH (5.3–8 mg/day) raised mortality to 42% versus 19% on placebo;
• children with PWS who are severely obese or have airway obstruction, sleep apnea or severe breathing problems, because of reports of sudden death;
• active cancer, and a higher risk of second tumors, especially meningiomas, in childhood cancer survivors who had head radiation;
• active proliferative or severe non-proliferative diabetic eye disease;
• raised pressure inside the skull, usually in the first 8 weeks, with an eye exam before starting;
• falling cortisol or thyroid function once GH begins;
• slipped hip growth plate, scoliosis progression and pancreatitis in children; ear infections and heart and vessel problems in Turner syndrome.

6. Interactions, blood sugar and GLP-1 drugs

GH opposes insulin. The label warns that somatropin may reduce insulin sensitivity, particularly at higher doses, can unmask impaired glucose tolerance or diabetes, and has been linked to new type 2 diabetes. It asks for periodic glucose checks in everyone, and closer monitoring with obesity, Turner syndrome or a family history of diabetes.

GLP-1 drugs fall under “injectable agents” for diabetes, but the label does not name them, and no trial has paired Genotropin with semaglutide or tirzepatide. For an adult with GH deficiency who also takes a GLP-1 drug, the practical point is that GH can push glucose up while the GLP-1 drug pushes it down, so diabetes medicines may need adjusting when either is started.

GH also does not solve GLP-1-related muscle loss. Adult trials enrolled people with diagnosed GH deficiency, measured lean mass on scans rather than strength, and lean mass includes water, which GH retains. The GLP-1 and muscle loss guide covers what is known about preserving lean mass during weight loss.

7. Daily Genotropin versus the weekly products

Pfizer now sells both a daily and a weekly GH. Ngenla (somatrogon) was approved in 2023 for children 3 and older with GH deficiency. In its pivotal trial, the daily comparator was somatropin at 0.034 mg/kg/day (Ngenla label).

In a crossover study of children who switched between the two regimens, life interference scores were 24.13 on daily injections versus 8.63 on weekly ones (Maniatis et al., 2022). Daily somatropin still has the wider label, the adult indication and decades of registry data. Which fits a given patient is a decision for the treating specialist.

8. Is Genotropin legal, and what should be recorded?

In the US, Genotropin is a prescription biologic and not a controlled substance. Growth hormone is listed in class S2.2.3 of the WADA 2026 Prohibited List, prohibited at all times as a non-Specified Substance.

A useful record lists the device and cartridge strength, the dose, the injection site, the date a cartridge was mixed (it is discarded 28 days later) and the date of each IGF-1 test. Swelling, joint pain, hand numbness, headaches with vision changes and glucose readings belong in the same log. The peptide tracker vs spreadsheet guide covers ways to keep those records together.

9. Genotropin FAQ

• Is Genotropin the same as HGH?

  Yes. Genotropin is somatropin, recombinant human growth hormone made in E. coli bacteria. Its 191 amino acids and molecular weight of about 22,124 daltons match pituitary GH, so it is the hormone itself, not an analog or a releasing peptide.

• What is Genotropin approved for?

  In the US: children with growth failure due to GH deficiency, Prader-Willi syndrome confirmed by genetic testing, small for gestational age without catch-up growth by age 2, Turner syndrome, or idiopathic short stature, and adults with GH deficiency of adult or childhood onset. It is not approved for aging, athletic performance or weight loss.

• What is the Genotropin dose?

  The label gives weekly doses by condition, divided into 6 or 7 daily injections: 0.16 to 0.24 mg/kg/week for childhood GH deficiency, 0.24 for Prader-Willi syndrome, 0.33 for Turner syndrome, up to 0.47 for idiopathic short stature and up to 0.48 for small for gestational age. Adults start around 0.2 mg/day, or no more than 0.04 mg/kg/week, and are adjusted by response and IGF-1.

• What is the difference between Genotropin MiniQuick and GoQuick?

  MiniQuick is a single-dose device holding one premeasured dose, from 0.2 to 2 mg, with no preservative; it is used once and discarded. GoQuick is a prefilled multi-dose pen sold in the UK and other markets that can be used for about a month. The current US label lists MiniQuick and the reusable Genotropin Pen 5 and Pen 12, not GoQuick.

• Is there a Genotropin shortage?

  In the UK, the Pituitary Foundation reported in February 2026 that the reusable Genotropin pen was out of stock in both strengths until at least early 2027, while MiniQuick and GoQuick remained available. The FDA drug shortage database showed no Genotropin entry when checked in November 2026.

• What are the side effects of Genotropin?

  In adult trials, peripheral swelling (17.5% vs 5.1% on placebo), joint pain (17.3% vs 4.2%), limb pain, edema and tingling were most common, usually early and dose-related. Labeled warnings include reduced insulin sensitivity, raised pressure inside the skull, tumor-related risks, slipped hip growth plate and scoliosis progression in children, and sudden death in some children with Prader-Willi syndrome.

• Can Genotropin be used with semaglutide or tirzepatide?

  No trial has studied Genotropin with a GLP-1 drug, and the label does not name GLP-1 drugs. It does say somatropin can reduce insulin sensitivity and that doses of insulin and oral or injectable diabetes drugs may need adjustment, so a combination belongs under a prescriber's supervision.

• Is Genotropin banned in sport?

  Yes. Growth hormone is listed in class S2.2.3 of the WADA 2026 Prohibited List and is prohibited at all times, in and out of competition.

10. Sources